文献阅读003：单细胞肿瘤浸润性髓系细胞的异质性(综述)

undefined

综述主要介绍了Mast、Dendritic、Monocyte、Macrophage、Neutrophils细胞，其中Neutrophils不是很详细，因此只总结了前4中细胞的亚群marker和特征。以思维导图形式总结在幕布，方便以后增删改查。

幕布文档链接: https://www.mubucm.com/doc/7V2nk7N6B_1 密码: 9adx

Mast

marker: TPSAB1, CPA3, KIT, MS4A2

1. high proportion in cancer than normal tissue;
2. down-regulate the expression of TNF;
3. 在不同癌症中其量与预后有正反关系;
4. 高表达VEGFA促进血管新生
5. 表达IL10,TGFB, 招募Treg促进免疫抑制
6. 高表达PD-L1
7. 释放CCL3、CCL5招募T和NK

Dendritic

Conventional DC (cDC)

cDC1

marker: XCR1, CLEC9A, BATF3, IRF8

1. mainly antitumor cDC2

marker: CLEC10A, FCER1A, CD1C, CD1E

1. 促进Th2、抑制Th17、与CD4+ T互作促进肿瘤
2. activates antitumor CD4+ conventional T cells (Tconvs) in the absence of Treg Plasmacytoid DC (pDC)

marker: MZB1, LILRA4, IRF7, IL3RA

1. immunosuppressive；
2. anti-tumor: release IFNα/β & TNFαLAMP3+ DC (mregDC)marker: LAMP3, BIRC3, CCR7, FSCN1
3. high expression of LAMP3, immune regulators CD274 & FAS, maturation genes (CD40 & CD80) and migratory genes (CCR7 & FSCN1)

2.enriched in intratumor & invasive margin tumor tissues;

1. originate: cDC1 and cDC2,;
2. high expression of CCL17, CCL19 & CCL22;
3. suppress CD8+ T cells self-renew and function through PD-L1/PD-1 pathway;
4. interact with CD8+ T cells from cDC1 ;
5. interact with Tregs from cDC2;recuit Treg;C3marker: CD88−CD1c+CD163+
6. pro-inflammatory: trigger the expansion of tissue-resident memory CD8+ T cells and enhance MHC expression
7. intermediated functional subtype between cDC2 and monocyte, produces TNFα as monocyte & IL23, IL12p70 as cDC2

Monocyte

Classical monocyte

marker: FCN1, CD14, S100A8, VCAN

Nonclassical monocyte

marker: FCN1, FCGR3A, LILRB2, LST1

Intermediate monocyte

marker: FCN1, CD14, FCGR3A

Macrophage

classically activated macrophages (M1)

1. 由Toll样受体配体如脂多糖和干扰素-γ诱导)
2. 表达促炎细胞因子和诱导型一氧化氮合酶
3. 增强抗肿瘤 Th1 反应并拮抗调节性免疫细胞的抑制活性alternatively activated macrophages (M2)
4. 由IL-4或IL-13诱导
5. 表达精氨酸酶1、CD206、CD163、IL-4R、TGF-β1和血小板衍生生长因子(PDGF)
6. 促进血管生成、肿瘤生长和转移Monocyte-like macrophagesmarker: FCN1, CD163, CD68FOLR2+ TRMmarker: FOLR2, MRC1
7. enrich: tumor stroma
8. prime effector CD8+ T cells
9. beneficial to survival TREM+ recruited macrophages
10. enrichment and activation of T cells and nature killer (NK) cells, which furtherly enhanced ICB therapyMDSCs-like macrophagesmarker: MARCO & TREM1
11. Myeloid-derived suppressor cellsTAM-like macrophagemarker: CD169, CX3CR1, TREM2
12. immature macrophage;
13. Enriched in TME with T cells infiltrated or excludedLYVE1+ TRMmarker: LYVE1, C1QC, PLTP, SEPP1
14. locate: adjacent to blood vesselsNLRP3+ TRMmarker: NLRP3, IL1B, CXCL2, EREG
15. promote the inflammatory responseAlveolar TRMmarker: PPARG, MARCO, MRC1, MSR1
16. canonical TRMISG15+ TAMmarker: ISG15, CXCL10, IFITM3, GBP1C1QC+ TAMmarker: C10A, C1QB, C1QG, APOE
17. phagocytosis and antigen presentation
18. originate: FCN1+ monocytes
19. locate: adjacent zonesSPP1+ TAMmarker: SPP1, VEGFA, GPNMB, FN1
20. angiogenesis;
21. worse prognosis;
22. associate with ICB drug resistance
23. interact with tumor-specific FAP+ fibroblasts to promote tumor progression
24. SPP1+ macrophages and TREM2+ macrophages might largely be overlapped with each other